Previous close | 1.9000 |
Open | 1.9000 |
Bid | 1.9500 |
Ask | 2.6500 |
Strike | 13.00 |
Expiry date | 2022-10-21 |
Day's range | 1.9000 - 1.9000 |
Contract range | N/A |
Volume | |
Open interest | 343 |
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
My name is Clint Tomlinson, and I'll be your host for today's call. The call will also be available for replay on Anavex's website at www.anavex.com. With us today is Dr. Christopher Missling, president and chief executive officer; and Sandra Boenisch, principal financial officer.
Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter en